BioLineRx/$BLRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioLineRx
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Ticker
$BLRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Hevel Modi'in, Israel
Employees
28
ISIN
US09071M3043
Website
BioLineRx Metrics
BasicAdvanced
$19M
-
-$0.00
0.86
-
Price and volume
Market cap
$19M
Beta
0.86
52-week high
$7.77
52-week low
$2.30
Average daily volume
1.4M
Financial strength
Current ratio
2.275
Quick ratio
2.016
Long term debt to equity
41.31
Total debt to equity
65.871
Interest coverage (TTM)
-1.95%
Profitability
EBITDA (TTM)
-14
Gross margin (TTM)
64.90%
Net profit margin (TTM)
-15.21%
Operating margin (TTM)
-74.85%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
-21.98%
Return on equity (TTM)
-20.03%
Valuation
Price to revenue (TTM)
291.68
Price to book
2.68
Price to tangible book (TTM)
5.35
Price to free cash flow (TTM)
-201.253
Free cash flow yield (TTM)
-0.50%
Free cash flow per share (TTM)
-2.19%
Growth
Revenue change (TTM)
91.68%
Earnings per share change (TTM)
-95.31%
3-year earnings per share growth (CAGR)
-58.04%
10-year earnings per share growth (CAGR)
-39.77%
BioLineRx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioLineRx stock?
BioLineRx (BLRX) has a market cap of $19M as of June 28, 2025.
What is the P/E ratio for BioLineRx stock?
The price to earnings (P/E) ratio for BioLineRx (BLRX) stock is 0 as of June 28, 2025.
Does BioLineRx stock pay dividends?
No, BioLineRx (BLRX) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next BioLineRx dividend payment date?
BioLineRx (BLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLineRx?
BioLineRx (BLRX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.